Event EndedCDF Oxford - What's the UK Life Sciences Strategy & where's the opportunity

The Magdalen Centre

1 Robert Robinson Avenue, OX4 4GA, Littlemore, England, United Kingdom

Graham Combe

0 位关注者

I host life science innovation events with Prof Tony Sedgwick where our mission is twofold. Firstly to support life science innovation business leaders with peer-to-peer thought-leadership business development support with our Agile Leaders CEO Forums. Secondly, to provide networking events focused on building business relationships between our Life Sciences Business Leaders with VCs, Pharma BD, Consultants and Service Providers that support innovation development. Our focus with our #biotechbuddies "in-person" events and our #coffeebuddies "virtual events" is to maintain a healthy balance between buyers and sellers to benefit all those that participate. The type of life sciences innovation companies that come to our events include biotech, medtech, digital health, tech bio & diagnostics. Generally, the companies that come to our events are in the first 5-6 years of development before commercialisation, from pre-clinical to Clinical Proof of Concept.Graham is an experienced relationship & business development professional with a demonstrated history of working in publishing, marketing and events within the life sciences and science-led industries. He work with the Nature publications for 15 years which stimulated his interest in working with innovation companies. He is skilled in publishing, marketing & event management, Graham has a deep understanding of the life science industries in the space before market approval and commercialization - essentially from the bench to phase 3.  He is a strong business development professional with a BSc (Hons) in Chemistry from University College London, U. of London.   Most recently as well as organising events, Graham is Business Development Director for Carocell Bio which is developing a scar-prevention therapeutic for patients both after surgery & after severe burns (two separate therapeutic programs). After raising about $2 million initially from various sources, Carocell Bio is now looking to raise a $10 million Series A to bring its therapies into the clinic.